Department of Nuclear Medicine, University Essen, Essen, Germany.
J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of somatostatin receptors (sst). The 2 compounds most often used in functional imaging with PET are (68)Ga-DOTATATE and (68)Ga-DOTATOC. Both ligands share a quite similar sst binding profile. However, the in vitro affinity of (68)Ga-DOTATATE in binding the sst subtype 2 (sst2) is approximately 10-fold higher than that of (68)Ga-DOTATOC. This difference may affect their efficiency in the detection of NET lesions because it is the sst2 that is predominantly overexpressed in NET. We thus compared the diagnostic value of PET/CT with both radiolabeled somatostatin analogs ((68)Ga-DOTATATE and (68)Ga-DOTATOC) in the same NET patients.
Forty patients with metastatic NETs underwent (68)Ga-DOTATOC and (68)Ga-DOTATATE PET/CT as part of the work-up before prospective peptide receptor radionuclide therapy. The performance of both imaging methods was analyzed and compared for the detection of individual lesions per patient and for 8 defined body regions. A region was regarded positive if at least 1 lesion was detected in that region. In addition, radiopeptide uptake in terms of the maximal standardized uptake value (SUVmax) was compared for concordant lesions and renal parenchyma.
Seventy-eight regions were found positive with (68)Ga-DOTATATE versus 79 regions with (68)Ga-DOTATOC (not significant). Overall, however, significantly fewer lesions were detected with (68)Ga-DOTATATE than with (68)Ga-DOTATOC (254 vs. 262, P < 0.05). Mean (68)Ga-DOTATATE SUVmax across all lesions was significantly lower than (68)Ga-DOTATOC (16.0 ± 10.8 vs. 20.4 ± 14.7, P < 0.01). Mean SUVmax for renal parenchyma was not significantly different between (68)Ga-DOTATATE and (68)Ga-DOTATOC (12.7 ± 3.0 vs. 13.2 ± 3.3).
(68)Ga-DOTATOC and (68)Ga-DOTATATE possess a comparable diagnostic accuracy for the detection of NET lesions, with (68)Ga-DOTATOC having a potential advantage. The approximately 10-fold higher affinity for the sst2 of (68)Ga-DOTATATE does not prove to be clinically relevant. Quite unexpectedly, SUVmax of (68)Ga-DOTATOC scans tended to be higher than their (68)Ga-DOTATATE counterparts.
在神经内分泌肿瘤(NET)患者中,比较两种放射性标记生长抑素类似物(68)Ga-DOTATOC 和(68)Ga-DOTATATE 的正电子发射断层扫描/计算机断层扫描(PET/CT)的诊断价值。
40 例转移性 NET 患者在肽受体放射性核素治疗前进行了(68)Ga-DOTATOC 和(68)Ga-DOTATATE PET/CT。分析并比较了两种成像方法对每位患者和 8 个定义的身体区域的单个病灶的检测性能。如果在该区域检测到至少 1 个病灶,则认为该区域为阳性。此外,比较了放射性肽在最大标准化摄取值(SUVmax)方面的摄取,比较了具有一致性病变和肾实质的摄取。
(68)Ga-DOTATATE 检测到 78 个阳性区域,(68)Ga-DOTATOC 检测到 79 个阳性区域(无显著差异)。然而,总的来说,(68)Ga-DOTATATE 检测到的病变明显少于(68)Ga-DOTATOC(254 个 vs. 262 个,P < 0.05)。所有病变的(68)Ga-DOTATATE SUVmax 平均值明显低于(68)Ga-DOTATOC(16.0 ± 10.8 vs. 20.4 ± 14.7,P < 0.01)。(68)Ga-DOTATATE 和(68)Ga-DOTATOC 的肾实质 SUVmax 平均值无显著差异(12.7 ± 3.0 vs. 13.2 ± 3.3)。
(68)Ga-DOTATOC 和(68)Ga-DOTATATE 对 NET 病变的检测具有相当的诊断准确性,(68)Ga-DOTATOC 具有潜在优势。(68)Ga-DOTATATE 对 sst2 的亲和力约高 10 倍,但这在临床上并不相关。出乎意料的是,(68)Ga-DOTATOC 扫描的 SUVmax 往往高于(68)Ga-DOTATATE 扫描的 SUVmax。